Selected research
Industry Research
Ulcerative Colitis Immunology Drugs Industry Research Report 2026
Market perspective
The global Ulcerative Colitis Immunology Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Ulcerative Colitis Immunology Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Ulcerative Colitis Immunology Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Ulcerative Colitis Immunology Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Ulcerative Colitis Immunology Drugs include Bristol-Myers Squibb Company, Celltrion Healthcare, Genentech USA, Inc., UCBCares, AbbVie Inc., AMGEN, Biogen, Pfizer Inc. and ROCHE, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Ulcerative Colitis Immunology Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (W Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/W Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Ulcerative Colitis Immunology Drugs Market by Company
Bristol-Myers Squibb Company
Celltrion Healthcare
Genentech USA, Inc.
UCBCares
AbbVie Inc.
AMGEN
Biogen
Pfizer Inc.
ROCHE
Janssen Biotech, Inc.
Ulcerative Colitis Immunology Drugs Segment by Type
Infliximab
Etanercept
Tofacitinib
Certolizumab Pegol
Golimumab
Adalimumab
Abatacept
Others
Ulcerative Colitis Immunology Drugs Segment by Application
Crohn's Disease(CD)
Ulcerative Colitis(UC)
Rheumatoid Arthritis
Ankylosing Spondylitis(AS)
Psoriasis(Ps)
Ulcerative Colitis Immunology Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Ulcerative Colitis Immunology Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Ulcerative Colitis Immunology Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Ulcerative Colitis Immunology Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Ulcerative Colitis Immunology Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Ulcerative Colitis Immunology Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Ulcerative Colitis Immunology Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Infliximab
- Etanercept
- Tofacitinib
- Certolizumab Pegol
- Golimumab
- Adalimumab
- Abatacept
- Others
Applications
- Crohn's Disease(CD)
- Ulcerative Colitis(UC)
- Rheumatoid Arthritis
- Ankylosing Spondylitis(AS)
- Psoriasis(Ps)
Companies covered
- Bristol-Myers Squibb Company
- Celltrion Healthcare
- Genentech USA, Inc.
- UCBCares
- AbbVie Inc.
- AMGEN
- Biogen
- Pfizer Inc.
- ROCHE
- Janssen Biotech, Inc.
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Ulcerative Colitis Immunology Drugs Market Size (2021-2032)
- 2.2.2 Global Ulcerative Colitis Immunology Drugs Sales (2021-2032)
- 2.2.3 Global Ulcerative Colitis Immunology Drugs Market Average Price (2021-2032)
- 2.3 Ulcerative Colitis Immunology Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Infliximab
- 2.3.3 Etanercept
- 2.3.4 Tofacitinib
- 2.3.5 Certolizumab Pegol
- 2.3.6 Golimumab
- 2.3.7 Adalimumab
- 2.3.8 Abatacept
- 2.3.9 Others
- 2.4 Ulcerative Colitis Immunology Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Crohn's Disease(CD)
- 2.4.3 Ulcerative Colitis(UC)
- 2.4.4 Rheumatoid Arthritis
- 2.4.5 Ankylosing Spondylitis(AS)
- 2.4.6 Psoriasis(Ps)
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Ulcerative Colitis Immunology Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Ulcerative Colitis Immunology Drugs Sales (W Units) of Manufacturers (2021-2026)
- 3.3 Global Ulcerative Colitis Immunology Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global Ulcerative Colitis Immunology Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global Ulcerative Colitis Immunology Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Ulcerative Colitis Immunology Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Ulcerative Colitis Immunology Drugs, Product Type & Application
- 3.8 Global Manufacturers of Ulcerative Colitis Immunology Drugs, Established Date
- 3.9 Global Ulcerative Colitis Immunology Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Bristol-Myers Squibb Company
- 4.1.1 Bristol-Myers Squibb Company Company Information
- 4.1.2 Bristol-Myers Squibb Company Business Overview
- 4.1.3 Bristol-Myers Squibb Company Ulcerative Colitis Immunology Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Bristol-Myers Squibb Company Ulcerative Colitis Immunology Drugs Product Portfolio
- 4.1.5 Bristol-Myers Squibb Company Recent Developments
- 4.2 Celltrion Healthcare
- 4.2.1 Celltrion Healthcare Company Information
- 4.2.2 Celltrion Healthcare Business Overview
- 4.2.3 Celltrion Healthcare Ulcerative Colitis Immunology Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Celltrion Healthcare Ulcerative Colitis Immunology Drugs Product Portfolio
- 4.2.5 Celltrion Healthcare Recent Developments
- 4.3 Genentech USA, Inc.
- 4.3.1 Genentech USA, Inc. Company Information
- 4.3.2 Genentech USA, Inc. Business Overview
- 4.3.3 Genentech USA, Inc. Ulcerative Colitis Immunology Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Genentech USA, Inc. Ulcerative Colitis Immunology Drugs Product Portfolio
- 4.3.5 Genentech USA, Inc. Recent Developments
- 4.4 UCBCares
- 4.4.1 UCBCares Company Information
- 4.4.2 UCBCares Business Overview
- 4.4.3 UCBCares Ulcerative Colitis Immunology Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 UCBCares Ulcerative Colitis Immunology Drugs Product Portfolio
- 4.4.5 UCBCares Recent Developments
- 4.5 AbbVie Inc.
- 4.5.1 AbbVie Inc. Company Information
- 4.5.2 AbbVie Inc. Business Overview
- 4.5.3 AbbVie Inc. Ulcerative Colitis Immunology Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 AbbVie Inc. Ulcerative Colitis Immunology Drugs Product Portfolio
- 4.5.5 AbbVie Inc. Recent Developments
- 4.6 AMGEN
- 4.6.1 AMGEN Company Information
- 4.6.2 AMGEN Business Overview
- 4.6.3 AMGEN Ulcerative Colitis Immunology Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 AMGEN Ulcerative Colitis Immunology Drugs Product Portfolio
- 4.6.5 AMGEN Recent Developments
- 4.7 Biogen
- 4.7.1 Biogen Company Information
- 4.7.2 Biogen Business Overview
- 4.7.3 Biogen Ulcerative Colitis Immunology Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Biogen Ulcerative Colitis Immunology Drugs Product Portfolio
- 4.7.5 Biogen Recent Developments
- 4.8 Pfizer Inc.
- 4.8.1 Pfizer Inc. Company Information
- 4.8.2 Pfizer Inc. Business Overview
- 4.8.3 Pfizer Inc. Ulcerative Colitis Immunology Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Pfizer Inc. Ulcerative Colitis Immunology Drugs Product Portfolio
- 4.8.5 Pfizer Inc. Recent Developments
- 4.9 ROCHE
- 4.9.1 ROCHE Company Information
- 4.9.2 ROCHE Business Overview
- 4.9.3 ROCHE Ulcerative Colitis Immunology Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 ROCHE Ulcerative Colitis Immunology Drugs Product Portfolio
- 4.9.5 ROCHE Recent Developments
- 4.10 Janssen Biotech, Inc.
- 4.10.1 Janssen Biotech, Inc. Company Information
- 4.10.2 Janssen Biotech, Inc. Business Overview
- 4.10.3 Janssen Biotech, Inc. Ulcerative Colitis Immunology Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Janssen Biotech, Inc. Ulcerative Colitis Immunology Drugs Product Portfolio
- 4.10.5 Janssen Biotech, Inc. Recent Developments
5 Global Ulcerative Colitis Immunology Drugs Market Scenario by Region
- 5.1 Global Ulcerative Colitis Immunology Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Ulcerative Colitis Immunology Drugs Sales by Region: 2021-2032
- 5.2.1 Global Ulcerative Colitis Immunology Drugs Sales by Region: 2021-2026
- 5.2.2 Global Ulcerative Colitis Immunology Drugs Sales by Region: 2027-2032
- 5.3 Global Ulcerative Colitis Immunology Drugs Revenue by Region: 2021-2032
- 5.3.1 Global Ulcerative Colitis Immunology Drugs Revenue by Region: 2021-2026
- 5.3.2 Global Ulcerative Colitis Immunology Drugs Revenue by Region: 2027-2032
- 5.4 North America Ulcerative Colitis Immunology Drugs Market Facts & Figures by Country
- 5.4.1 North America Ulcerative Colitis Immunology Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Ulcerative Colitis Immunology Drugs Sales by Country (2021-2032)
- 5.4.3 North America Ulcerative Colitis Immunology Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Ulcerative Colitis Immunology Drugs Market Facts & Figures by Country
- 5.5.1 Europe Ulcerative Colitis Immunology Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Ulcerative Colitis Immunology Drugs Sales by Country (2021-2032)
- 5.5.3 Europe Ulcerative Colitis Immunology Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.5.9 Nordic Countries
- 5.6 Asia Pacific Ulcerative Colitis Immunology Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific Ulcerative Colitis Immunology Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Ulcerative Colitis Immunology Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Ulcerative Colitis Immunology Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Ulcerative Colitis Immunology Drugs Market Facts & Figures by Country
- 5.7.1 South America Ulcerative Colitis Immunology Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Ulcerative Colitis Immunology Drugs Sales by Country (2021-2032)
- 5.7.3 South America Ulcerative Colitis Immunology Drugs Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Ulcerative Colitis Immunology Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Ulcerative Colitis Immunology Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Ulcerative Colitis Immunology Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Ulcerative Colitis Immunology Drugs Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Ulcerative Colitis Immunology Drugs Sales by Type (2021-2032)
- 6.1.1 Global Ulcerative Colitis Immunology Drugs Sales by Type (2021-2032) & (W Units)
- 6.1.2 Global Ulcerative Colitis Immunology Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global Ulcerative Colitis Immunology Drugs Revenue by Type (2021-2032)
- 6.2.1 Global Ulcerative Colitis Immunology Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Ulcerative Colitis Immunology Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global Ulcerative Colitis Immunology Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Ulcerative Colitis Immunology Drugs Sales by Application (2021-2032)
- 7.1.1 Global Ulcerative Colitis Immunology Drugs Sales by Application (2021-2032) & (W Units)
- 7.1.2 Global Ulcerative Colitis Immunology Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global Ulcerative Colitis Immunology Drugs Revenue by Application (2021-2032)
- 7.2.1 Global Ulcerative Colitis Immunology Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Ulcerative Colitis Immunology Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global Ulcerative Colitis Immunology Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Ulcerative Colitis Immunology Drugs Value Chain Analysis
- 8.1.1 Ulcerative Colitis Immunology Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Ulcerative Colitis Immunology Drugs Production Mode & Process
- 8.2 Ulcerative Colitis Immunology Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Ulcerative Colitis Immunology Drugs Distributors
- 8.2.3 Ulcerative Colitis Immunology Drugs Customers
9 Global Ulcerative Colitis Immunology Drugs Analyzing Market Dynamics
- 9.1 Ulcerative Colitis Immunology Drugs Industry Trends
- 9.2 Ulcerative Colitis Immunology Drugs Industry Drivers
- 9.3 Ulcerative Colitis Immunology Drugs Industry Opportunities and Challenges
- 9.4 Ulcerative Colitis Immunology Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst